Ivonescimab Improves Survival in Squamous NSCLC Trial

A survival advantage against active treatment

In the phase 3 HARMONi-6 trial conducted in China, ivonescimab plus chemotherapy reduced the hazard of death compared with tislelizumab plus chemotherapy among patients with advanced squamous non-small-cell lung cancer. Median overall survival was 27.9 months with ivonescimab and 23.7 months with tislelizumab, while the reported hazard ratio for death was 0.66.

That hazard ratio represents an estimated 34% reduction in the instantaneous risk of death during the observed study period. It should not be interpreted as meaning that patients lived 34% longer. The 4.2-month difference between medians is a descriptive summary of when half the patients in each group had died; the hazard ratio incorporates survival experience across follow-up.

Overall survival is a patient-centered endpoint that is less vulnerable than progression-free survival to differences in scan timing or interpretation. Because HARMONi-6 was randomized and double-blind, the comparison supports a causal treatment effect within the population, care setting and follow-up studied, assuming the trial’s conduct and prespecified interim testing were sound.

The result nevertheless remains an interim analysis. Its interpretation depends on the confidence interval, number of deaths, statistical boundary, data cutoff and duration of follow-up reported in the peer-reviewed publication. Those details determine the estimate’s precision and whether the survival advantage met the trial’s prespecified standard rather than emerging from repeated examination of accumulating data.

How HARMONi-6 tested the combination

HARMONi-6 was a randomized, double-blind phase 3 study enrolling 532 patients in China with advanced squamous NSCLC. Participants received chemotherapy with either ivonescimab or tislelizumab, providing an active-control comparison rather than a placebo-controlled test.

Ivonescimab is a bispecific antibody designed to inhibit both programmed cell death protein 1, or PD-1, and vascular endothelial growth factor, or VEGF. Tislelizumab inhibits PD-1. The trial therefore tested whether adding VEGF-directed activity within a bispecific molecule could improve outcomes beyond a PD-1-based chemoimmunotherapy regimen.

Randomization helps balance measured and unmeasured prognostic factors at baseline. Blinding reduces the potential for differential treatment decisions, supportive care or outcome assessment. Most importantly, the active comparator asks a clinically relevant efficacy question: whether the investigational combination can outperform another checkpoint inhibitor combined with chemotherapy.

The comparator also shapes what can be concluded. The study establishes relative efficacy against tislelizumab plus chemotherapy in the trial setting. It does not directly establish superiority, equivalence or noninferiority relative to pembrolizumab-based chemoimmunotherapy or other regimens used in US practice because those treatments were not randomized comparators.

What the result supports now

The interim findings strengthen the evidence that dual PD-1 and VEGF targeting with ivonescimab can translate into an overall survival benefit when combined with chemotherapy in advanced squamous NSCLC. This is more consequential than a progression-free survival advantage alone because it suggests that delayed progression was not offset by later mortality, treatment toxicity or post-progression outcomes during the period analyzed.

For evidence assessment, the finding establishes proof of superiority over the specific active-control regimen in the enrolled Chinese population if the prespecified interim significance threshold was met. It also provides a rationale for continued regulatory evaluation and for trials that compare the regimen with standards used in other health systems.

The evidence does not, by itself, establish a US standard of care. FDA decisions consider the complete efficacy and safety dataset, trial integrity, applicability to the proposed population, manufacturing quality and the benefit-risk balance. A statistically persuasive trial result and a regulatory authorization are related but distinct conclusions.

US clinicians would also need to understand how outcomes vary by PD-L1 expression, disease extent, smoking history, age, performance status and other clinically relevant features. Subgroup findings can inform consistency, but HARMONi-6 was not necessarily powered to establish separate survival effects within every subgroup. Apparent differences between small subgroups should therefore be treated cautiously.

Limits that matter for US interpretation

Geography is the most visible limitation. All participants were enrolled in China, and differences in patient characteristics, supportive care, subsequent anticancer therapy and access to later-line drugs can affect overall survival. A treatment effect may remain biologically relevant across populations, but its magnitude cannot automatically be assumed to be identical in US practice.

The choice of tislelizumab is another important constraint. It is an active PD-1 inhibitor, making this a rigorous efficacy comparison, but it is not the principal first-line checkpoint inhibitor benchmark for advanced squamous NSCLC in the United States. Without a head-to-head trial against a commonly used US regimen, cross-trial comparisons would be confounded by differences in eligibility, follow-up, staging, biomarker distribution and subsequent treatment.

Safety requires equal attention. VEGF inhibition can introduce clinically important risks that differ from those associated with PD-1 blockade alone, while chemotherapy adds hematologic and other toxicities. The survival result cannot substitute for detailed review of grade 3 or worse adverse events, treatment discontinuations, fatal events and toxicities associated with bleeding, thrombosis, hypertension or impaired wound healing.

Interim analyses also evolve. Additional deaths can move the hazard ratio and median estimates, clarify whether survival curves remain separated and reveal delayed toxicities. The mature analysis will be especially important if proportional hazards are uncertain or if the curves cross, because a single hazard ratio may then incompletely describe the treatment effect over time.

Finally, economic and implementation questions remain. A bispecific product may affect infusion workflows, monitoring and acquisition costs differently from established regimens. Those considerations require regulatory labeling, mature safety data and comparative value analyses; they cannot be resolved from the survival endpoint alone.

Questions clinicians ask

Does a hazard ratio of 0.66 mean patients lived 34% longer?

No. It indicates an estimated 34% lower instantaneous hazard of death with ivonescimab plus chemotherapy across the analyzed follow-up. Median survival was 27.9 versus 23.7 months, a 4.2-month difference, but neither measure predicts how much longer an individual patient will live.

Is this enough to replace current US first-line therapy?

Not by itself. HARMONi-6 compared ivonescimab with tislelizumab, not directly with the checkpoint inhibitor regimens most commonly used for first-line squamous NSCLC in the United States. US adoption would also require regulatory review, complete safety information and confidence that the findings apply to US patients and treatment pathways.

How much does the China-only population limit the result?

It limits generalizability more than internal validity. Randomization supports the comparison within HARMONi-6, but population characteristics, subsequent therapies and health-system practices may differ from those in the United States. Confirmatory multinational evidence would reduce uncertainty about whether the magnitude of benefit travels across settings.

What should be checked in the mature report?

Key items include the final hazard ratio and confidence interval, duration of follow-up, number and timing of deaths, survival after progression, subgroup consistency and treatment exposure. Detailed rates of severe adverse events, discontinuation and VEGF-associated complications will be essential to judge whether the survival gain produces a favorable overall benefit-risk balance.

References

1. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China — PubMed, 2026
2. Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version — National Cancer Institute, 2026
3. Drug Approvals and Databases — US Food and Drug Administration, 2026